# Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

> **NCT02257619** · PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 9 (actual)

## Conditions studied

- NSCLC (Non-small Cell Lung Carcinoma)

## Interventions

- **DRUG:** Itacitinib
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT02257619
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09-24
- **Primary completion:** 2016-02
- **Final completion:** 2016-04-05
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Sponsor decision to not initiate part 2 due to slow enrollment and competing trials.
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02257619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02257619, "Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02257619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*